stockrow
Friday 6 November 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
- Revenue
- −98.4%
- EPS
- +80.9%
- Free cash flow
- −5.22%
Quarter to September 2026, against a year earlier
0.52
0.02
+4.00%
Follow APRE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 1 | 2 | 0 | 0 | (30.0%) | 0 | 1 | 2 | +91.6% | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | (15) | (16) | (28) | (53) | (37) | (113) | (14) | (13) | (13) | (14) | (2.3%) | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2,449.73) | (862.42) | (4,408.54) | 0.00 | (4,408.5) pt | ||||||
| Net income | — | (15) | (16) | (28) | (53) | (37) | (113) | (14) | (13) | (13) | (14) | (2.3%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.27 | 0.04 | 0.00 | n/m | |||||
| Earnings | — | (263.49) | (269.12) | (93.40) | (50.60) | (34.80) | (67.99) | (3.95) | (2.35) | (1.93) | (0.70) | (45.9%) | ||||||
| Cash flow | — | (242.67) | (264.30) | (89.00) | (39.55) | (35.41) | (15.09) | (3.37) | (2.46) | (1.97) | (0.24) | (45.2%) | ||||||
| Capex | — | 0.00 | (0.06) | (0.10) | (0.02) | 0.00 | 0.00 | (0.03) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (242.67) | (264.37) | (89.10) | (39.57) | (35.41) | (15.09) | (3.39) | (2.46) | (1.97) | (0.24) | (45.2%) | ||||||
| Book value | — | 0.00 | 1,059.87 | 414.01 | 73.22 | 46.52 | 15.48 | 4.69 | 3.50 | 1.90 | 0.64 | n/m | ||||||
| Shares, m | — | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 6 | 7 | 32 | +80.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 12.06 | 19.45 | 97.70 | 10.5 | ||||||
| P/B | — | — | — | — | — | — | — | 1.07 | 0.94 | 0.45 | 0.82 | 0.8 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | (3.14) | (31.65) | (34.76) | (11.6) | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.29 | 0.35 | 0.70 | 0.78 | 0.4 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (14) | (15) | (27) | (42) | (38) | (25) | (12) | (14) | (13) | (13) | (1.0%) | |||||
| Capex | — | — | 0 | 0 | 0 | — | — | 0 | 0 | — | 0 | +27.0% | ||||||
| Free cash flow | — | (14) | (15) | (27) | (42) | (38) | (25) | (12) | (14) | (13) | (13) | (1.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 61 | 124 | 77 | 49 | 27 | 18 | 20 | 13 | 34 | (20.0%) | |||||
| Net debt | — | — | (66) | (130) | (89) | (53) | (29) | (22) | (23) | (15) | (38) | (19.3%) | ||||||
| Shareholders’ equity | — | — | 61 | 124 | 77 | 50 | 26 | 17 | 19 | 12 | 34 | (20.3%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (46.02) | (47.04) | (28.11) | (47.24) | (49.63) | (259.05) | (54.11) | (55.58) | (63.14) | (53.24) | (17.1) pt | |||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 0.00 | (42.66) | (77.08) | (53.04) | (58.51) | (299.83) | (67.08) | (71.47) | (79.37) | (62.83) | (79.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 14 | 13 | 17 | 16 | 9 | 7 | 8 | 8 | — | (7.7%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.19 | 0.04 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 6 Nov 2026
Aprea Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $6.6M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| FBLG FibroBiologics Inc. | $6.4M | — (loss-making) | — | — | n/m | +21.59% (above 0%: growing) | — | 0.00% | Compare |
| ENVB Enveric Biosciences, Inc. | $6.3M | — (loss-making) | — (loss-making) | −7.28% (below 0%: shrinking) | n/m | −29.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| APRE Aprea Therapeutics, Inc. | $6.2M | — (loss-making) | — (loss-making) | −98.40% (below 0%: shrinking) | n/m | −5.22% (below 0%: shrinking) | 100.00% | 0.00% | |
| AIM AIM ImmunoTech Inc. | $6.1M | — (loss-making) | — (loss-making) | +4.00% (above 0%: growing) | n/m | −167.46% (below 0%: shrinking) | 80.77% | (13,511.54%) | Compare |
| EVGN Evogene Ltd. | $6.0M | — (loss-making) | — (loss-making) | −35.02% (below 0%: shrinking) | n/m | +17.72% (above 0%: growing) | 40.63% | (738.62%) | Compare |
| CNSP CNS Pharmaceuticals, Inc. | $5.9M | — (loss-making) | — | — | n/m | +33.70% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XCUR Exicure, Inc. | $5.8M | — (loss-making) | — (loss-making) | −80.51% (below 0%: shrinking) | n/m | +65.38% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $6.2M | — | — | −57.76% | — | +19.66% | 80.77% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
10.49%
Sphera
9.99%
Soleus Capital Master Fund, LP
9.99%
Soleus Private Equity Fund III,L.P.
9.99%
Entities associated with Vestal Point Capital, LP{
9.99%
Squadron Master Fund LP
9.99%
Lytton-Kambara Foundation
9.99%
AIGH Partners
9.99%
WVP Emerging
9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement